Secondary outcomes assessed self-reported ingestive behavior and blood-oxygenation-level-dependent functional magnetic resonance imaging with food photos
An analysis of the FDA Adverse Event Reporting System (FAERS) through Q4 2024 identified nausea as the leading reported event for semaglutide products, though FAERS reports are voluntary and cannot establish incidence rates [5]
The patients who do best on any GLP-1-based medication are the ones who use the appetite reduction as an opportunity to rebuild the habits around food, protein intake, sleep and movement
Potentially, but with caveats
When I was recruited to my first academic job as an Assistant Professor at The University of Maryland, I asked my Chairman Joseph McLaughlin when I would be promoted to Associate Professor (the next step up)
Heerspink HJL, Stefansson BV, Correa-Rotter R, et al